EP1968583A4 - Composes, essais et methodes de traitement - Google Patents
Composes, essais et methodes de traitementInfo
- Publication number
- EP1968583A4 EP1968583A4 EP06847822A EP06847822A EP1968583A4 EP 1968583 A4 EP1968583 A4 EP 1968583A4 EP 06847822 A EP06847822 A EP 06847822A EP 06847822 A EP06847822 A EP 06847822A EP 1968583 A4 EP1968583 A4 EP 1968583A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- screens
- compounds
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75191305P | 2005-12-20 | 2005-12-20 | |
US84330406P | 2006-09-08 | 2006-09-08 | |
PCT/US2006/048583 WO2007075772A2 (fr) | 2005-12-20 | 2006-12-20 | Composes, essais et methodes de traitement |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1968583A2 EP1968583A2 (fr) | 2008-09-17 |
EP1968583A4 true EP1968583A4 (fr) | 2010-09-15 |
Family
ID=38218558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06847822A Withdrawn EP1968583A4 (fr) | 2005-12-20 | 2006-12-20 | Composes, essais et methodes de traitement |
Country Status (7)
Country | Link |
---|---|
US (2) | US8324262B2 (fr) |
EP (1) | EP1968583A4 (fr) |
JP (1) | JP2009521454A (fr) |
CN (1) | CN101674826A (fr) |
AU (1) | AU2006331754B9 (fr) |
CA (1) | CA2633500A1 (fr) |
WO (1) | WO2007075772A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005077344A2 (fr) | 2003-08-29 | 2005-08-25 | The Brigham And Women's Hospital, Inc. | Inhibiteurs de la necrose cellulaire |
CN101353351A (zh) * | 2007-07-25 | 2009-01-28 | 杨更亮 | 新的2,3,3a,4-四氢硫色烯并[4,3-c]吡唑类抗炎、抗真菌化合物 |
JP5645663B2 (ja) | 2007-08-15 | 2014-12-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ネクロトーシスのヘテロ環式抑制剤 |
WO2010075561A1 (fr) * | 2008-12-23 | 2010-07-01 | President And Fellows Of Harvard College | Inhibiteurs de la nécroptose de petite taille moléculaire |
BRPI0902039B8 (pt) | 2009-06-09 | 2021-05-25 | Anhanguera Educacional Ltda | composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais |
CA2778174C (fr) | 2009-11-13 | 2018-02-20 | Merck Serono S.A. | Derives d'amine pyrazol tricycliques comme inhibiteurs de pi3k |
CN102086212B (zh) * | 2009-12-03 | 2013-06-12 | 沈阳药科大学 | 抗真菌剂-2,3,4,5-四氢-4H-苯并[b]噻喃并[4,3-c]吡唑-2-甲酰胺衍生物 |
WO2011133964A2 (fr) | 2010-04-23 | 2011-10-27 | Massachusetts Eye And Ear Infirmary | Compositions et procédés de conservation de cellules de photorécepteurs et de cellules épithéliales de pigment rétinien |
WO2012061045A2 (fr) | 2010-11-01 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Méthodes et compositions permettant de préserver les cellules ganglionnaires de la rétine |
US9643977B2 (en) | 2011-03-11 | 2017-05-09 | President And Fellows Of Harvard College | Necroptosis inhibitors and methods of use therefor |
WO2013013826A1 (fr) * | 2011-07-27 | 2013-01-31 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Inhibiteurs de la nécroptose pour le traitement de maladies inflammatoires du tractus gastro-intestinal |
CA2888805C (fr) * | 2011-10-21 | 2020-07-14 | Massachusetts Eye And Ear Infirmary | Procedes et compositions pour la promotion de la regeneration axonale et de la fonction nerveuse |
TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 (二) |
JP2016514693A (ja) | 2013-03-15 | 2016-05-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハイブリッド型ネクロトーシス阻害剤 |
CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
CL2013003785A1 (es) * | 2013-12-30 | 2014-07-11 | Univ Pontificia Catolica Chile | Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos |
WO2016027253A1 (fr) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utilisés comme inhibiteurs de la rip1 kinase en tant que médicaments |
SG11201704764PA (en) | 2014-12-11 | 2017-07-28 | Harvard College | Inhibitors of cellular necrosis and related methods |
JP6683712B2 (ja) * | 2014-12-24 | 2020-04-22 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ,ベイジン | ネクローシス阻害薬 |
CN105078975A (zh) * | 2015-07-22 | 2015-11-25 | 南方医科大学 | Necrostatin-1作为中性粒细胞凋亡促进剂的应用 |
JP7066186B2 (ja) | 2016-02-19 | 2022-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満の処置のための方法及び医薬組成物 |
US10064845B2 (en) * | 2016-05-11 | 2018-09-04 | Cumberland Pharmaceuticals, Inc. | Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists |
US20180094248A1 (en) * | 2016-06-30 | 2018-04-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Necroptosis Signaling as a Therapeutic Target for Alzheimer's Disease |
CN106619619A (zh) * | 2017-01-06 | 2017-05-10 | 浙江大学 | 化合物hubin‑1在制备肝脏炎症性疾病预防和/或治疗药物中的用途 |
JP2020509009A (ja) | 2017-02-27 | 2020-03-26 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キナーゼ阻害剤としての複素環式アミド |
BR112019020967A2 (pt) * | 2017-04-05 | 2020-05-05 | Revolution Medicines Inc | métodos e reagentes para analisar interfaces de proteína-proteína |
WO2020044206A1 (fr) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utiles en tant qu'inhibiteurs de kinases destinés à être utilisés dans le traitement du cancer |
CN108997183B (zh) * | 2018-09-03 | 2020-02-07 | 深圳大学 | 一种二氟甲基化试剂及其制备方法与应用 |
CN111978311A (zh) * | 2019-05-21 | 2020-11-24 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
CN112263576A (zh) * | 2020-09-30 | 2021-01-26 | 浙江大学 | 化合物zju-37在制备肝脏疾病预防和/或治疗药物中的应用 |
WO2024039250A1 (fr) * | 2022-08-19 | 2024-02-22 | Pastoral Greenhouse Gas Research Limited | Inhibiteurs des méthanogènes |
CN115227692A (zh) * | 2022-09-05 | 2022-10-25 | 中国医学科学院基础医学研究所 | Reblastatin在制备治疗慢性惊厥的药物中的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028493A2 (fr) * | 1999-10-15 | 2001-04-26 | President And Fellows Of Harvard College | Inhibiteurs a petite molecule de la necrose |
EP1270567A1 (fr) * | 2000-03-21 | 2003-01-02 | Mitsui Chemicals, Inc. | Derives pyrazoline ou tetrahydropyridazine et utilisation medicinale de ceux-ci |
US6756394B1 (en) * | 1999-10-15 | 2004-06-29 | President And Fellow Of Harvard College | Small molecule inhibitors of necrosis |
WO2006086358A2 (fr) * | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Inhibiteurs de kinesines mitotiques |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706766B2 (en) | 1999-12-13 | 2004-03-16 | President And Fellows Of Harvard College | Small molecules used to increase cell death |
US6723736B2 (en) * | 2000-10-10 | 2004-04-20 | Theracos, Inc. | Tricyclic compounds and uses thereof |
HRP20020305A8 (en) * | 2002-04-10 | 2009-03-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
JP2004161662A (ja) * | 2002-11-13 | 2004-06-10 | Abbott Japan Co Ltd | 1h−イミダゾキノリン誘導体 |
WO2005077344A2 (fr) | 2003-08-29 | 2005-08-25 | The Brigham And Women's Hospital, Inc. | Inhibiteurs de la necrose cellulaire |
US6887993B1 (en) * | 2003-11-12 | 2005-05-03 | Kosan Biosciences, Inc. | 11-O-methylgeldanamycin compounds |
US20100087453A1 (en) | 2006-10-10 | 2010-04-08 | President And Fellows Of Harvard College | Compounds, screens, and methods of treatment |
JP5645663B2 (ja) | 2007-08-15 | 2014-12-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ネクロトーシスのヘテロ環式抑制剤 |
-
2006
- 2006-12-20 JP JP2008547482A patent/JP2009521454A/ja active Pending
- 2006-12-20 US US12/086,792 patent/US8324262B2/en active Active
- 2006-12-20 CA CA002633500A patent/CA2633500A1/fr not_active Abandoned
- 2006-12-20 CN CN200680053077A patent/CN101674826A/zh active Pending
- 2006-12-20 EP EP06847822A patent/EP1968583A4/fr not_active Withdrawn
- 2006-12-20 AU AU2006331754A patent/AU2006331754B9/en active Active
- 2006-12-20 WO PCT/US2006/048583 patent/WO2007075772A2/fr active Application Filing
-
2012
- 2012-10-31 US US13/665,263 patent/US20130158024A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028493A2 (fr) * | 1999-10-15 | 2001-04-26 | President And Fellows Of Harvard College | Inhibiteurs a petite molecule de la necrose |
US6756394B1 (en) * | 1999-10-15 | 2004-06-29 | President And Fellow Of Harvard College | Small molecule inhibitors of necrosis |
EP1270567A1 (fr) * | 2000-03-21 | 2003-01-02 | Mitsui Chemicals, Inc. | Derives pyrazoline ou tetrahydropyridazine et utilisation medicinale de ceux-ci |
WO2006086358A2 (fr) * | 2005-02-10 | 2006-08-17 | Merck & Co., Inc. | Inhibiteurs de kinesines mitotiques |
Non-Patent Citations (5)
Title |
---|
FATEEN A K ET AL: "Synthesis of delta2-pyrazolines and 1-naphthols", EGYPTIAN JOURNAL OF CHEMISTRY, NATIONAL INFORMATION AND DOCUMENTATION CENTRE (NIDOC), CAIRO; EG, vol. 15, no. 4, 1 January 1972 (1972-01-01), pages 329 - 334, XP009136253, ISSN: 0449-2285 * |
HAMMAM A E G ET AL: "SYNTHESIS OF NOVEL TRICYCLIC HETEROCYCLIC COMPOUNDS AS POTENTIAL ANTICANCER AGENTS USING CHROMANONE AND THIOCHROMANONE AS SYNTHONS", INDIAN JOURNAL OF CHEMISTRY, JODHPUR, IN, vol. 42B, 1 August 2003 (2003-08-01), pages 1985 - 1993, XP009046925 * |
SANGWAN ET AL: "Use of characteristic proton NMR chemical shifts to differentiate diastereoisomeric [1]benzopyrano[4,3-c]pyrazoles, pyrazolo[4,3-c]quinolines, and related compounds", JOURNAL OF CHEMICAL RESEARCH, SCIENCE REVIEWS LTD, GB, no. 1, 1 January 1987 (1987-01-01), pages 22 - 23, XP009135036, ISSN: 0308-2342 * |
SINHA A K ET AL: "SYNTHESIS OF 3 3A-TRANS-CIS-2 PHENYLACETYL-3-ARYLTETRAHYDROINDENO-NAP HTHO-1 2-C-PYRAZOLES AND HEXAHYDROBENZO-6 7-CYCLOHEPTA-1 2-C-PYRAZOLES AS ANTIIMPLANTATION AGENTS", INDIAN JOURNAL OF CHEMISTRY. SECTION B: ORGANIC AND MEDICINAL CHEMISTRY, COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (C S I R), IN, vol. 30, no. 7, 1 January 1991 (1991-01-01), pages 684 - 692, XP008075792, ISSN: 0376-4699 * |
VENKATESWARLU PEESAPATI ET AL: "Nitrogen heterocyclic systems: synthesis of 3,3a-trans adn cis-2-acetyl/phenyl-3-arylhexahydrobenzo(6,7)cyclohepta(1,2-c)pyrazoles", JOURNAL OF CHEMICAL RESEARCH, SCIENCE REVIEWS LTD, GB, vol. 9, 1 January 2001 (2001-01-01), pages 372 - 374, XP009136257, ISSN: 0308-2342 * |
Also Published As
Publication number | Publication date |
---|---|
AU2006331754B9 (en) | 2013-07-11 |
WO2007075772A2 (fr) | 2007-07-05 |
WO2007075772A3 (fr) | 2009-02-19 |
US20130158024A1 (en) | 2013-06-20 |
CN101674826A (zh) | 2010-03-17 |
AU2006331754A2 (en) | 2008-08-14 |
CA2633500A1 (fr) | 2007-07-05 |
AU2006331754A1 (en) | 2007-07-05 |
EP1968583A2 (fr) | 2008-09-17 |
US8324262B2 (en) | 2012-12-04 |
JP2009521454A (ja) | 2009-06-04 |
US20100190836A1 (en) | 2010-07-29 |
AU2006331754B2 (en) | 2013-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1968583A4 (fr) | Composes, essais et methodes de traitement | |
IL182011A0 (en) | Treatment screening methods | |
EP2076134A4 (fr) | Composés, criblages, et procédés de traitement | |
ZA200705459B (en) | Treatment method | |
EP1945284A4 (fr) | Dispositifs de type seringue, leurs elements constitutifs et procedes de formation d'un agent medicamenteux dans lesdits dispositifs | |
GB0506759D0 (en) | Combination treatment methods | |
IL188430A0 (en) | Treatment of tumors | |
IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
IL188728A0 (en) | Methods of treating epileptogenesis | |
HK1117780A1 (en) | Compounds and methods for the treatment of cancer | |
ZA200704610B (en) | Treatment apparatus | |
GB2430002B (en) | Well treatment | |
ZA200709024B (en) | Method of well treatment and construction | |
IL184330A0 (en) | Treatment apparatus | |
GB0525540D0 (en) | New treatment | |
GB0511769D0 (en) | Treatment | |
GB0502171D0 (en) | Well treatment | |
IL226362A0 (en) | compounds, and methods for treating cancer | |
EP1793813A4 (fr) | Traitement du trouble d'hyperactivite avec deficit de l'attention (thada) | |
GB0426196D0 (en) | Methods of treatment | |
GB0424085D0 (en) | Well treatment | |
GB0426141D0 (en) | Treatment | |
EP1896500A4 (fr) | Gliomédine: fragments et procédés | |
GB0523637D0 (en) | Process and compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080714 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20090219 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/513 20060101ALI20090306BHEP Ipc: C07D 225/04 20060101ALI20090306BHEP Ipc: A61P 25/28 20060101ALI20090306BHEP Ipc: A61K 31/4178 20060101AFI20090306BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100816 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/513 20060101ALI20100810BHEP Ipc: A61P 25/28 20060101ALI20100810BHEP Ipc: A61K 31/4178 20060101ALI20100810BHEP Ipc: C07D 225/04 20060101AFI20100810BHEP |
|
17Q | First examination report despatched |
Effective date: 20110505 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150527 |